Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 18, Issue 8, Pages 755-765
Publisher
Wiley
Online
2016-03-22
DOI
10.1111/dom.12665
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Obesity Paradox in Type 2 Diabetes Mellitus: Relationship of Body Mass Index to Prognosis
- (2015) Pierluigi Costanzo et al. ANNALS OF INTERNAL MEDICINE
- The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
- (2015) Sanjoy K Paul et al. Cardiovascular Diabetology
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus
- (2014) Nathaniel R. Smilowitz et al. CIRCULATION
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective
- (2014) M. Fisher DIABETES OBESITY & METABOLISM
- Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus - a retrospective nationwide study
- (2014) U. M. Mogensen et al. DIABETES OBESITY & METABOLISM
- Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations
- (2014) Elisabetta Patorno et al. DIABETOLOGIA
- Effect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression
- (2013) M. Katout et al. AMERICAN JOURNAL OF HYPERTENSION
- Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
- (2013) D. M. Nathan et al. DIABETES CARE
- Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
- (2013) Louise E Robinson et al. BMJ Open
- Heart Disease and Stroke Statistics—2013 Update
- (2012) Alan S. Go et al. CIRCULATION
- The effect of glucagon-like peptide 1 on cardiovascular risk
- (2012) Jacob Sivertsen et al. Nature Reviews Cardiology
- One-to-many propensity score matching in cohort studies
- (2012) Jeremy A. Rassen et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- A systematic review of validated methods for identifying heart failure using administrative data
- (2012) Jane S. Saczynski et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Covariate Selection in High-Dimensional Propensity Score Analyses of Treatment Effects in Small Samples
- (2011) Jeremy A. Rassen et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
- (2011) Robert Ratner et al. Cardiovascular Diabetology
- Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials
- (2011) Matteo Monami et al. Experimental Diabetes Research
- Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database
- (2010) J. H. Best et al. DIABETES CARE
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population
- (2010) Peter M. Wahl et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data
- (2009) Sebastian Schneeweiss et al. EPIDEMIOLOGY
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
- (2009) Peter C. Austin STATISTICS IN MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now